Breaking News

Kerry Says Mideast Cease-Fire Talks to Continue Tomorrow
Tweet TWEET

Pluristem Achieves Milestone Towards Completion of Its New GMP Manufacturing Facility for Commercial Production of PLX Cells

Pluristem Achieves Milestone Towards Completion of Its New GMP Manufacturing
Facility for Commercial Production of PLX Cells

HAIFA, Israel, Oct. 23, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc.
(Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell
therapies, announced today a milestone in the build-out of its new clinical
Good Manufacturing Process (cGMP) manufacturing facility for its Placental
eXpanded (PLX) cells in MATAM Park, Haifa, Israel. Pluristem has initiated the
Installation Qualification (IQ) validation process through Biopharmax Group
Ltd., the company which is handling the build-out of Pluristem's facility.
Following successful IQ, an Operation Qualification (OQ) will begin which
marks the final stage of the build-out process prior to handing the facility
over to Pluristem. The IQ/OQ validation includes systems such as the Heating,
Ventilation, and Air Conditioning (HVAC), the Water for Injection (WFI), the
Oil Free Air (OFA) and gas process systems.

Once constructed, the new facility will have the capacity to produce
commercial grade PLX cells which will complement Pluristem's current
manufacturing facility, with over 40,000 square feet. Once constructed, and
assuming the PLX cells product candidates are successfully developed and
approved by the regulators, the new facility would have the capacity to
produce PLX cells for the treatment of over 150,000 patients annually
estimated by Pluristem at $1 billion in production value.

Zami Aberman, Chairman and CEO of Pluristem commented, "We are extremely
pleased with the progress of erecting one of the most technological advanced
commercial grade cell manufacturing facility in the world."

Pluristem had first announced in July 2011 that it is expanding its
manufacturing facility as part of Pluristem's strategy to develop its
"top-of-the-line" intellectual property and manufacture its cell therapy
product candidates in July 2011. Pluristem's new regenerative medicine
facility is designed specifically to meet both FDA and EMA regulatory
requirements, as well as the standards outlined by the Israeli Ministry of
Health. For more information, please visit:
http://www.pluristem.com/index.php?option=com_content&view=article&id=176:-april-6&catid=4&Itemid=104

About Pluristem Therapeutics

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) is a leading developer
of placenta-based cell therapies. The Company's patented PLX (PLacental
eXpanded) cells are a drug delivery platform that releases a cocktail of
therapeutic proteins in response to a host of local and systemic inflammatory
and ischemic diseases. PLX cells are grown using the company's proprietary 3D
micro-environmental technology and are an "off-the-shelf" product that
requires no tissue matching prior to administration. Pluristem is focusing on
the development of PLX cells administered locally to potentially treat
systemic diseases and potentially obviating the need to use the intravenous
route.

Data from two phase I studies indicate that Pluristem's first PLX product
candidate, PLX-PAD, is safe and potentially effective for the treatment of end
stage peripheral artery disease when given locally. Additionally, Pluristem is
developing PLX-PAD for cardiac ischemia, PLX-BMP for Acute Radiation Exposure,
Bone Marrow Transplant Failure and Chemotherapy induced Bone Marrow Aplasia,
PLX-ORTHO for orthopedic indications and PLX-PAH for Pulmonary Hypertension in
collaboration with United Therapeutics. Pluristem's pre-clinical animal models
have demonstrated PLX cells are also potentially effective in other
inflammatory/ischemic indications, including diastolic heart failure,
inflammatory bowel disease, neuropathic pain and pulmonary fibrosis.

Pluristem has a strong patent and patent applications portfolio, company-owned
GMP certified manufacturing and research facilities, strategic relationships
with major research institutions and a seasoned management team. For more
information visit www.pluristem.com and follow Pluristem on Twitter@Pluristem,
the content of which is not part of this press release.

The Pluristem Therapeutics Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6882

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and federal securities laws. For example, when we discuss our new
manufacturing facility, its construction, its validation process, its planned
capacity for production of PLX cells and estimated production value assuming
the PLX cells product candidates are successfully developed and approved by
the regulators, that PLX cells are safe and can potentially treat PAD or that
PLX cells are also potentially effective in other inflammatory/ischemic
indications, we are using forward-looking statements. These forward-looking
statements are based on the current expectations of the management of
Pluristem only, and are subject to a number of factors and uncertainties that
could cause actual results to differ materially from those described in the
forward-looking statements. The following factors, among others, could cause
actual results to differ materially from those described in the
forward-looking statements: changes in technology and market requirements; we
may encounter delays or obstacles in launching and/or successfully completing
our clinical trials; our products may not be approved by regulatory agencies,
our technology may not be validated as we progress further and our methods may
not be accepted by the scientific community; we may be unable to retain or
attract key employees whose knowledge is essential to the development of our
products; unforeseen scientific difficulties may develop with our process; our
products may wind up being more expensive than we anticipate; results in the
laboratory may not translate to equally good results in real surgical
settings; results of preclinical studies may not correlate with the results of
human clinical trials; our patents may not be sufficient; our products may
harm recipients; changes in legislation; inability to timely develop and
introduce new technologies, products and applications; loss of market share
and pressure on pricing resulting from competition, which could cause the
actual results or performance of Pluristem to differ materially from those
contemplated in such forward-looking statements. Except as otherwise required
by law, Pluristem undertakes no obligation to publicly release any revisions
to these forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated events. For a
more detailed description of the risks and uncertainties affecting Pluristem,
reference is made to Pluristem's reports filed from time to time with the
Securities and Exchange Commission.

CONTACT: Pluristem Therapeutics Inc.:
        
         William Prather R.Ph., M.D. Sr. VP Corporate Development
         1-303-883-4954
         William.PratherMD@pluristem.com
        
         Daya Lettvin
         Investor & Media Relations Director
         +972-54-674-5580
         daya@pluristem.com

Pluristem Therapeutics Inc. Logo